NeuroPace, Inc. (NPCE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$19.29
Price Target
$19.00
Target Range
$16.00 — $22.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-29.2x
Forward PEG—
Implied Growth+37.1%
Median Target$19.00
Analyst Spread31.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$16
-17.1%
Consensus
$19
-1.5%
Bull Case
$22
+14.0%
NPCE Price Target Analysis
Updated May 8, 2026As of May 8, 2026, NeuroPace, Inc. (NPCE) has a Wall Street consensus price target of $19.00, based on estimates from 10 covering analysts. With the stock currently trading at $19.29, this represents a potential downside of -1.5%. The company has a market capitalization of $648M.
Analyst price targets range from a low of $16.00 to a high of $22.00, representing a 32% spread in expectations. The median target of $19.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NPCE trades at a trailing P/E of -29.2x. Analysts expect EPS to grow +37.1% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+57.1%
Avg Forward P/E21.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LIVNLivaNova PLC | $3.9B | $70.92 | $75.88 | +7.0% | Buy | 16.8x | 14 |
 ELMDElectromed, Inc. | $222M | $26.86 | $38.00 | +41.5% | Buy | 24.4x | 4 |
 MDTMedtronic plc | $99.9B | $77.96 | $109.50 | +40.5% | Buy | 14.1x | 49 |
 ABTAbbott Laboratories | $151.3B | $87.01 | $128.71 | +47.9% | Buy | 15.9x | 41 |
 BSXBoston Scientific Corporation | $84.1B | $56.58 | $91.33 | +61.4% | Buy | 16.7x | 43 |
 NVCRNovoCure Limited | $1.9B | $16.83 | $33.50 | +99.0% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 ISRGIntuitive Surgical, Inc. | $161.1B | $453.49 | $622.60 | +37.3% | Buy | 43.8x | 55 |
 TNDMTandem Diabetes Care, Inc. | $1.3B | $18.47 | $31.62 | +71.2% | Buy | — | 39 |
 INSPInspire Medical Systems, Inc. | $1.3B | $45.57 | $91.33 | +100.4% | Hold | 24.5x | 27 |
Upside Potential Comparison
INSPNVCRTNDMINVABSXABTELMDMDTSee NPCE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NPCE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NPCE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNPCE — Frequently Asked Questions
Quick answers to the most common questions about buying NPCE stock.
What is the NPCE stock price target for 2026?
Wall Street's consensus price target for NPCE is $19, -1.5% from its current price of $19.29. The below-market target from 10 analysts suggests limited near-term appreciation.
Is NPCE a buy, sell, or hold?
NPCE has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies -1.5% downside from current levels.
Is NPCE stock overvalued or undervalued?
NPCE's current price is $19.29 with a consensus target of $19 (-1.5% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can NPCE stock go?
The most bullish Wall Street analyst has a price target of $22 for NPCE, while the most conservative target is $16. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NPCE stock?
NPCE is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NPCE stock forecast?
The 12-month NPCE stock forecast based on 10 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $16 (bear case) to $22 (bull case). The median consensus rating is "Buy".
Should I buy NPCE stock?
Analysts are cautious on NPCE, with 0 Sell ratings and a price target of $19 (-1.5% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NPCE price targets vary so much?
NPCE analyst price targets range from $16 to $22, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.